Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis

Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis

ObjectiveCapivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment remains uncertain. This study aimed to evaluate the cost-effectiveness of capivasertib plus fulvestrant v...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yitian Lang, Qingqing Chai, Yan Lin, Bin Wu, Xiaoyan Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pharmacology
Subjects:	cost-effectiveness HR-positive breast cancer capivasertib plus fulvestrant partitioned survival approach economic evaluation
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1495082/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
by: Caifeng Jia, et al.
Published: (2025-04-01)

Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance
by: Juliane Albrecht, et al.
Published: (2025-01-01)

“Four years of remission with fulvestrant monotherapy in advanced endometrioid adenocarcinoma of the endometrium Harboring an ESR1 Mutation: A case Report”
by: João Felipe Feldmann, et al.
Published: (2025-06-01)

Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells
by: Keenan L. Flynn, et al.
Published: (2024-11-01)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024-10-01)

Current feasibility of endocrine therapy for breast cancer
by: I. V. Vysotskaya
Published: (2014-07-01)

Oestrogen Receptor Alpha in Myocyte Maintains Muscle Regeneration in Duchenne Muscular Dystrophy
by: Xiaofei Huang, et al.
Published: (2025-04-01)

Metástasis duodenogástrica por cáncer de mama: reporte de caso
by: Daniel Andrés Santa Botero, et al.
Published: (2017-12-01)

OncoPSM: an interactive tool for cost-effectiveness analysis using partitioned survival models in oncology trial
by: Xulong Qiu, et al.
Published: (2025-08-01)

First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution
by: Guillermo Valencia, et al.
Published: (2024-12-01)

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer
by: Karam Aboud, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as first-line treatment for advanced squamous non-small cell lung cancer
by: Xiaoyan You, et al.
Published: (2025-03-01)

Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations
by: Moumita Chaki, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
by: Yiling Ding, et al.
Published: (2025-12-01)

Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer
by: Lian Tang, et al.
Published: (2025-07-01)

Sugemalimab plus chemotherapy vs. chemotherapy for treatment of Chinese patients with esophageal squamous cell carcinoma: a cost effectiveness analysis to inform decision making
by: Qiuping Chen, et al.
Published: (2025-06-01)

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-07-01)

Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Longfeng Zhang, et al.
Published: (2025-07-01)

Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer
by: Ying Xu, et al.
Published: (2024-12-01)

Heart rate cost as a tool for monitoring recovery between acute training sessions
by: José Morais Souto Filho, et al.
Published: (2024-12-01)

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
by: Chunyan Yan, et al.
Published: (2025-03-01)

The Demazure product extended to biwords
by: William Q. Erickson
Published: (2025-01-01)

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
by: Xichun Hu, et al.
Published: (2025-05-01)

Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study
by: Grazia Arpino, et al.
Published: (2025-05-01)

Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
by: Wai-kit Ming, et al.
Published: (2020-08-01)

Survival outcomes in hormone receptor-negative breast cancer among BRCA carriers versus noncarriers in western Sweden
by: Anna-Karin Tzikas, et al.
Published: (2025-04-01)

A prognostic signature for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
by: Yincheng Liu, et al.
Published: (2025-07-01)

STRATEGY OF HR DEVELOPMENT AT HIGH-TECH ENTERPRISES
by: Valentyna Kyriy, et al.
Published: (2017-11-01)

The relationship between the degree of adopting human resource change leadership role and human resource attribution in sustainable enterprises
by: Diem Thi Pham, et al.
Published: (2024-12-01)

Specific Introduction of Hrm-System in Trade Organizations
by: N. P. Tishkina, et al.
Published: (2024-01-01)

The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study
by: Kuan-Yu Tseng, et al.
Published: (2025-07-01)

SIFAT-SIFAT DASAR INTEGRAL HENSTOCK
by: Lexy J. Sinay
Published: (2012-12-01)

Congruences modulo $4$ for the number of $3$-regular partitions
by: Ballantine, Cristina, et al.
Published: (2023-11-01)

A Partitioning-Based Approach to Variable Selection in WLW Model for Multivariate Survival Data
by: Wenjian Tian, et al.
Published: (2025-04-01)

Link between HR practices and organizational performance in small firms: A case for manufacturing sector of Pakistan
by: Muhammad Fayyaz Sheikh, et al.
Published: (2015-12-01)

The plus side of size: relationship between brand experience and consumers trust and loyalty on a Brazilian brand
by: Bianca Carvalho da Silva, et al.
Published: (2024-12-01)

Understanding Motivation: An Effective Tool for Managers
by: Ian Bessell, et al.
Published: (2002-08-01)

Understanding Conflict in the Workplace
by: Julie Gatlin, et al.
Published: (2002-08-01)

Transformational Leadership: The Transformation of Managers and Associates
by: John Hall, et al.
Published: (2002-08-01)